MENLO PARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, and neurology disorders by modulating the effects of the hormone cortisol, today announced the Court for the District of New Jersey issued a decision that Teva Pharmaceuticals does not infringe any asserted claims of Corcept's U.S. Patents 10,195,214 and 10,842,800, both of which concern methods of safely administering Korlym® with drugs that are strong CYP3A4 inhibitors.
"This disappointing decision is based on legal and factual errors we are confident will be reversed on appeal," said Joseph K. Belanoff, MD, Corcept's Chief Executive Officer. "Our patents describe medical discoveries that have greatly expanded the therapeutic options available to patients suffering from Cushing's syndrome, which is why the FDA added them to Korlym's prescribing ...